

**Kyowa Hakko Kirin Co., Ltd.****Appendix to the Consolidated Financial Statements**

Fiscal 2008

(April 1, 2008 - March 31, 2009)

	<b>Index</b>	<b>Page</b>
<b>Consolidated</b>	I. Financial results	
	1. Income	1
	2. Results by segment	1
	3. Other income	2
	4. Extraordinary income/losses	2
	5. R&D expenses	2
	6. Capital expenditure	3
	7. Depreciation expenses	3
	8. Number of staff	3
	9. Key indicators	4
	II. Subsidiaries and affiliates	5
<b>Non-Consolidated</b>	III. Financial results	
	1. Net sales by division	6
<b>R&amp;D Pipeline</b>		8

This document was made as a supplement to the Kessan Tanshin (financial report) for the period of the fiscal year ending March 31, 2009. This document contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.

## 1. Trends in Consolidated Financial Results

### 1. Trends in income

Millions of yen, rounded down

	April 1, 2007 to March 31, 2008	April 1, 2008 to March 31, 2009						April 1, 2009 to December 31, 2009	
	Full year results (A)	April 1 to September 30 results	April 1 to December 31 results	Full year forecast	Full year results (B)	Comparison with previous year		April 1 to September 30 forecasts	April 1 to December 31 forecasts
						Change (B-A)	Percentage change		
<b>Net sales</b>	392,119	247,769	362,278	457,000	460,183	68,064	117%	185,000	300,000
<b>Gross Profit</b>	144,917	109,345	159,870		200,297	55,379	138%	--	--
Selling, general and administrative	105,527	80,180	117,174		154,910	49,383	147%	--	--
Operating income (Before amortization of goodwill)	39,390	33,962	49,893	56,096	54,983	15,593	140%	19,151	33,977
<b>Operating income</b>	39,390	29,164	42,696	46,500	45,387	5,996	115%	14,500	27,000
Other income	4,863	3,093	3,736		5,871	1,008		--	--
Other expenses	6,257	1,899	3,166		4,846	(1,411)		--	--
<b>Recurring income</b>	37,996	30,357	43,265	47,000	46,412	8,416	122%	15,000	27,500
Extraordinary income	7,988	--	--		6,075	(1,913)		--	--
Extraordinary expenses	7,169	4,769	13,981		21,550	14,381		--	--
<b>Net income before income taxes</b>	38,815	25,588	29,284	35,000	30,937	(7,877)	80%	13,500	26,000
Corporate, local and enterprise taxes	15,228	10,150	13,555		20,799	5,570		--	--
Corporate tax adjustment	(35)	6,798	4,799		(1,865)	(1,830)		--	--
Income in minority interests	144	353	445		276	132		--	--
<b>Net income</b>	23,477	8,258	10,483	13,000	11,726	(11,750)	50%	6,500	13,000
EPS before goodwill amortization (#/share)	59.03	22.79	30.80	39.36	37.14			19.43	34.81

\*Before goodwill amortization are the amounts before the amortization of goodwill arising from the reverse acquisition (share exchange with Kirin Pharma)

### 2. Trends in results by segment

#### (1) Results by operating segment

Millions of yen, rounded down

	April 1, 2007 to March 31, 2008	April 1, 2008 to March 31, 2009						April 1, 2009 to December 31, 2009	
	Full year results (A)	April 1 to September 30 results	April 1 to December 31 results	Full year forecast	Full year results (B)	Comparison with previous year		April 1 to September 30 forecasts	April 1 to December 31 forecasts
						Change (B-A)	Percentage change		
<b>Net sales</b>	392,119	247,769	362,278	457,000	460,183	68,064	117%	185,000	300,000
Pharmaceuticals	138,377	108,719	161,337	209,000	210,448	72,071	152%	98,000	153,000
Bio-Chemicals	86,820	45,711	67,545	89,000	88,464	1,644	102%	42,000	70,000
Chemicals	108,007	57,204	77,322	90,000	89,204	(18,802)	83%	31,000	50,000
Food	43,324	20,804	32,834	43,000	42,468	(855)	98%	--	--
Other	48,998	36,572	54,502	71,000	68,733	19,734	140%	30,000	52,000
Total	425,527	269,011	393,542	502,000	499,319	73,791	117%	201,000	325,000
Eliminations	(33,407)	(21,241)	(31,264)	(45,000)	(39,135)	(5,727)	--	(16,000)	(25,000)
<b>Operating income</b> (Before goodwill amortization)	39,390	29,164	42,696	46,500	45,387	5,996	115%	14,500	27,000
Pharmaceuticals	19,961	19,699	29,662	32,500	34,832	14,870	174%	12,000	21,500
		<i>24,013</i>	<i>36,134</i>	<i>41,128</i>	<i>43,460</i>			<i>16,314</i>	<i>27,971</i>
Bio-Chemicals	9,688	5,216	7,425	8,200	8,342	(1,345)	86%	2,000	3,800
		<i>5,529</i>	<i>7,894</i>	<i>8,826</i>	<i>8,967</i>			<i>2,312</i>	<i>4,269</i>
Chemicals	7,169	2,960	3,532	3,400	(47)	(7,216)	--	100	1,000
		<i>2,984</i>	<i>3,569</i>	<i>3,449</i>	<i>2</i>			<i>124</i>	<i>1,037</i>
Food	1,576	565	999	1,100	1,086	(489)	69%	--	--
		<i>711</i>	<i>1,218</i>	<i>1,393</i>	<i>1,379</i>			<i>--</i>	<i>--</i>
Other	838	687	1,060	1,300	1,094	255	131%	400	700
		<i>687</i>	<i>1,060</i>	<i>1,300</i>	<i>1,094</i>			<i>400</i>	<i>700</i>
Total	39,234	29,128	42,680	46,500	45,308	6,073	115%	14,500	27,000
		<i>33,926</i>	<i>49,877</i>	<i>56,096</i>	<i>54,904</i>			<i>19,151</i>	<i>33,977</i>
Eliminations	155	35	15	--	78	(77)	51%	--	--

\*Figures representing goodwill before amortization have been italicized

#### (2) Overseas sales

Millions of yen, rounded down

	April 1, 2007 to March 31, 2008	April 1, 2008 to March 31, 2009				
	Full year results	Percentage of consolidated sales	April 1 to September 30 results	Percentage of consolidated sales	Full year results	Percentage of consolidated sales
<b>Overseas sales</b>	75,217	19.2%	59,032	23.8%	88,770	19.3%
America	23,149	5.9%	23,635	9.5%	31,023	6.7%
Europe	22,475	5.7%	12,792	5.2%	22,631	4.9%
Asia	29,052	7.4%	22,290	9.0%	34,254	7.4%
Other regions	539	0.1%	314	0.1%	860	0.2%
<b>Total consolidated net sales</b>	392,119	100.0%	247,769	100.0%	460,183	100.0%

### 3. Trends in other income

Millions of yen, rounded down

	April 1, 2007 to March 31, 2008	April 1, 2008 to March 31, 2009		
	Full year results (A)	April 1 to September 30 results	Full year results (B)	Change (B-A)
<b>Other income</b>	4,863	3,093	5,871	1,008
Interest received	528	351	688	159
Dividend income	1,274	668	2,394	1,120
Foreign exchange gain	--	442	135	135
Income from equity method investments	1,125	694	1,211	86
Other	1,935	936	1,441	(493)
<b>Other expenses</b>	6,257	1,899	4,846	(1,411)
Interest expense	327	300	523	195
Foreign exchange loss	1,034	--	--	(1,034)
Loss from disposal of fixed assets	1,441	856	2,483	1,042
Other	3,453	742	1,839	(1,613)

### 4. Trends in extraordinary income / losses

Millions of yen, rounded down

	April 1, 2007 to March 31, 2008	April 1, 2008 to March 31, 2009		
	Full year results (A)	April 1 to September 30 results	Full year results (B)	Change (B-A)
<b>Extraordinary income</b>	7,988	--	6,075	(1,913)
Gain on sale of shares in affiliates	--	--	4,721	4,721
Gain on sale of investment in affiliates	--	--	1,354	1,354
Gain on sale of fixed assets	7,471	--	--	(7,471)
Other income	517	--	--	(517)
<b>Extraordinary losses</b>	7,169	4,769	21,550	14,381
Loss from revaluation of investment securities	--	180	6,634	6,634
Asset impairment losses	2,264	1,931	5,724	3,459
Integration-related expenses	2,831	1,895	5,514	2,682
Compensation payment	--	--	1,937	1,937
Extraordinary depreciation of fixed assets	--	762	762	762
Loss from revaluation of investment in affiliates	1,372	--	--	(1,372)
Expense related to early retirement support system	700	--	--	(700)
Other expenses	--	--	977	977

### 5. Trends in R&D expenses

Billions of yen, rounded down

	April 1, 2007 to March 31, 2008	April 1, 2008 to March 31, 2009					April 1, 2009 to December 31, 2009	
	Full year results (A)	April 1 to September 30 results	April 1 to December 31 results	Full year forecast	Full year results (B)	Change (B-A)	April 1 to September 30 forecasts	April 1 to December 31 forecasts
<b>R&amp;D (Consolidated)</b>	34.1	25.9	36.9	51.7	48.3	14.2	23.7	36.3
R&D to Net sales ratio (%)	8.7%	10.5%	10.2%	11.3%	10.5%	1.8%	12.9%	12.1%
Pharmaceuticals	28.1	23.0	32.5	45.1	42.6	14.4	21.1	32.3
(R&D to Net sales ratio) (%)	20.4%	21.2%	20.2%	21.6%	20.3%	-0.1%	21.6%	21.1%
Bio-Chemicals	3.9	1.8	2.7	4.2	3.6	(0.3)	2.0	3.0
Chemicals	1.0	0.5	0.8	1.3	1.1	0.1	0.6	0.9
Food	0.9	0.4	0.6	0.9	0.9	(0.0)	--	--
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

## 6. Trends in capital expenditure

Billions of yen, rounded down

	April 1, 2007 to March 31, 2008	April 1, 2008 to March 31, 2009				April 1, 2009 to December 31, 2009		
	Full year results (A)	April 1 to September 30 results	April1 to December 31 results	Full year forecast	Full year results (B)	Change (A - B)	April1 to September 30 forecast	April1 to December 31 forecast
<b>Capital expenditure (Consolidated)</b>	14.7	8.5	12.9	23.5	18.4	3.7	19.8	28.3
Pharmaceuticals	4.2	3.6	5.5	12.4	9.6	5.4	11.8	17.5
Bio-Chemicals	4.1	2.0	3.8	5.7	5.3	1.1	3.4	5.6
Chemicals	4.3	2.4	2.9	4.7	4.3	(0.0)	4.4	5.0
Food	1.9	0.3	0.4	0.4	0.5	(1.3)	--	--
Other	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0
Eliminations	--	(0.0)	(0.0)	(0.0)	(1.5)	(1.5)	--	--

## 7. Trends in depreciation expenses

Billions of yen, rounded down

	April 1, 2007 to March 31, 2008	April 1, 2008 to March 31, 2009				April 1, 2009 to December 31, 2009		
	Full year results (A)	April 1 to September 30 results	April1 to December 31 results	Full year forecast	Full year results (B)	Change (A - B)	April1 to September 30 forecast	April1 to December 31 forecast
<b>Depreciation expenses (Consolidated)</b>	14.3	9.6	14.3	20.0	18.7	4.4	8.8	14.0
Pharmaceuticals	3.9	4.6	6.6	9.2	8.3	4.4	3.8	5.9
Bio-Chemicals	5.5	2.4	3.7	5.3	5.0	(0.5)	2.6	4.3
Chemicals	3.7	2.0	3.0	4.3	4.2	0.4	2.2	3.5
Food	0.9	0.4	0.7	0.9	0.9	0.0	--	--
Other	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.1
Eliminations	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	0.0	--	--

## 8. Trends in number of staff

(Number of people)

	April 1, 2007 to March 31, 2008	April 1, 2008 to March 31, 2009	Change
	Year-end (A)	Year-end (B)	Change (B-A)
<b>Number of staff at end of term (Consolidated)</b>	6,073	7,256	1,183
Pharmaceuticals	2,880	4,594	1,714
Bio-Chemicals	1,458	1,528	70
Chemicals	505	514	9
Food	586	--	(586)
Other	285	326	41
Whole company (combined)	359	294	(65)

## 9. Trends in key indicators

### (1) Exchange rate

	April 1, 2007 to March 31, 2008	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009	
	Full year results	April 1 to September 30 results	April 1 to December 31 results	Full year results	April 1 to September 30 forecasts	April 1 to December 31 forecasts
US Dollar (Yen/US\$)	114	106	103	101	90	90
Euro (Yen/Euro)	162	163	151	143	120	120

### (2) Operating indicators (Consolidated)

	April 1, 2007 to March 31, 2008	April 1, 2008 to March 31, 2009	
	Full year results	April 1 to September 30 results	Full year results
(before goodwill amortization) Net income per share (yen)	59.03	22.79 14.43	37.14 20.43
Return on equity	9.5%	1.5%	2.2%
Recurring income to total capital ratio	9.8%	4.1%	6.4%
Operating income to sales ratio	10.0%	11.8%	9.9%
Total assets (million yen)	394,081	748,454	699,041
Net assets (million yen)	256,758	551,817	543,070
Equity ratio	64.5%	73.1%	77.0%
Net assets per share (yen)	639.69	952.77	938.42
ROIC (Return on invested capital)*	13.8%	8.2%	14.5%

$$* \text{ ROIC (\%)} = \frac{\text{Operating income}}{(\text{Fixed assets} + \text{Working capital})} \times 100$$

Note: Calculations are based on operating income before amortization of goodwill and fixed assets not including goodwill.

#### IV. Subsidiaries and affiliates

(As of March 31, 2009)

Segment	Type	Company name	Percentage owned (direct and indirect)	Principal business
Pharmaceuticals	Consolidated subsidiary	Kyowa Medex Co., Ltd.	100.0%	Manufacture and sale of diagnostic reagents
		Kirin Kunpeng (China) Bio-Pharmaceutical Co., Ltd.	70.0%	Manufacture and sale and of pharmaceuticals (China)
		Kyowa Medical Promotion Co., Ltd.	100.0%	Sales promotion of pharmaceuticals
		Kyowa Hakko Kirin America, Inc.	100.0%	Holding company for administration and management of US subsidiaries (US)
		BioWa, Inc.	100.0%	Out-licensing and promotion of anti-body technology and development of therapeutic antibodies (US Company)
		Kyowa Hakko Kirin California, Inc.	100.0%	Generate new candidate substances and develop pharmaceuticals (US)
		Hematech, Inc.	100.0%	Technology research for manufacture of therapeutic antibody (US)
		Hematech-GAC Venture, LLC	51.0%	Technology research for manufacture of therapeutic antibody (US)
		Jeil-Kirin Pharmaceutical Inc.	90.0%	Sales of pharmaceuticals (Korea)
		Kirin Pharmaceuticals Co., Ltd.	100.0%	Sales of pharmaceuticals (Taiwan)
		Kyowa Hakko Kirin (Hong Kong) Co., Ltd.	100.0%	Sales of pharmaceuticals (Hong kong)
		Kyowa Hakko Kirin (Singapore) Pte. Ltd.	100.0%	Sales of pharmaceuticals (Singapore)
Kyowa Hakko Kirin (Thailand) Co., Ltd.	100.0%	Operations suspended June 30, 2008		
Bio-Chemicals	Consolidated subsidiary	Kyowa Hakko Bio Co., Ltd.	100.0%	Manufacture and sale of pharmaceutical and industrial raw materials, and health care products
		Daiichi Fine Chemical Co., Ltd.	100.0%	Manufacture and sale of active pharmaceutical ingredients and pharmaceutical intermediates
		Biokyowa Inc.	100.0%	Manufacture and sale of amino acids (US Company)
		Shanghai Kyowa Amino Acid Co., Ltd.	70.0%	Manufacture and sale of amino acids (China Company)
		Kyowa Hakko U.S.A., Inc.	100.0%	Sale and import/export of fine chemicals including amino acids (US Company)
		Kyowa Hakko Europe GMBH	100.0%	Sale and import/export of fine chemicals including amino acids (Germany Company)
		Kyowa Italiana Farmaceutici S.R.L.	100.0%	Sale and import/export of fine chemicals including amino acids (Italy Company)
		Kyowa Hakko (H.K.) Co., Ltd.	100.0%	Sale and import/export of fine chemicals including amino acids (Hong Kong Company)
		Kyowa Hakko Bio U.S. Holdings, Inc.	100.0%	Holding company for administration and management of US subsidiaries (US)
		Kyowa Wellness Co., Ltd.	100.0%	Sale of healthcare products
Shinwa Pharmaceutical Co., Ltd.	100.0%	Sale of herbal medicines and health foods		
		Kyowa Engineering Co., Ltd.	100.0%	Design and installation of plant facilities and equipment
Chemicals	Consolidated subsidiary	Kyowa Hakko Chemical Co., Ltd.	100.0%	Manufacture and sale of chemicals
	Affiliate accounted for by the equity method	J-PLUS Co., Ltd.	50.0%	Manufacture and sale of plasticizers
		Kurogane Kasei Co., Ltd.	40.0%	Manufacture and sale of plasticizers, fine chemicals, etc.
Food	Affiliate accounted for by the equity method	Kyowa Hakko Food Specialties Co., Ltd.	47.4%	Manufacture and sale of seasonings, bakery products and ingredients and other foods
		Kyowa F.D. Foods Co., Ltd.	47.4%	Manufacture and sale of freeze-dried foods
		Ohland Foods Co., Ltd.	47.4%	Manufacture and sale of bakery products, etc.
		Kyowa HiFoods Co. Ltd.	47.4%	Import and sale of foods, etc.
		Aji-Nihon Co., Ltd.	22.0%	Manufacture and sale of foods and seasonings, etc.
		Zenmi Foods Inc.	23.7%	Manufacture and sale of seasonings
Other	Consolidated subsidiary	Miyako Kagaku Co., Ltd.	52.9%	Wholesale sales of pharmaceuticals, chemicals, foods, etc.
		Chiyoda Kaihatsu Co., Ltd.	100.0%	Transportation, insurance, sale of food, etc.
		Kashiwagi Corporation	56.0%	Wholesale sales of chemicals, pharmaceutical products, construction materials, etc.
	Affiliate accounted for by the equity method	Japan Synthetic Alcohol Co., Ltd.	33.3%	Manufacture and sale of industrial use alcohol

Changes to the scope of consolidation

Newly consolidated: Two companies: Kirin Pharma Company, Limited and Kyowa Hakko Bio Co., Ltd.

Eliminated: Ltd.

Companies changed from subsidiaries to affiliates accounted for by the equity method

Kyowa Hakko Food Specialties Co., Ltd., Kyowa F.D. Foods Co., Ltd., Ohland Foods Co., Ltd. and Kyowa HiFoods Co. Ltd.

### III. Net sales by division (Items and main products presented on a Non-Consolidated basis)

Kyowa Hakko Kogyo Co., Ltd.

Billions of yen, rounded down

Pharmaceuticals division (Non-Consolidated)	April 1, 2007 to March 31, 2008	April 1, 2008 to March 31, 2009				April 1, 2009 to December 31, 2009	
	Full year results	April 1 to September 30 results	April 1 to December 31 results	Full year forecast (January 30)	Full year results	April 1 to September 30 forecasts	April 1 to December 31 forecasts
<b>Pharmaceutical division total</b>	127.3	99.2	147.5	188.3	191.3	89.3	139.4
<b>Central nervous system agents</b>							
<i>Depakene</i>	10.5	5.3	8.3	10.7	10.7	5.4	8.5
<i>Topina</i>	0.1	0.3	0.6	1.0	0.9	0.7	1.1
<b>Sensory organ agents</b>							
<i>Patanol</i>	4.3	1.4	2.2	4.9	6.6	2.1	3.2
<b>Circulatory organ agents</b>							
<i>Coniel</i>	25.4	11.6	18.1	22.9	23.1	11.3	17.3
<i>Inovan + Pre Dopa</i>	4.1	1.8	2.9	3.7	3.7	1.7	2.7
<i>Coversyl</i>	--	2.6	4.0	5.0	5.0	2.3	3.6
<b>Digestive organ agents</b>							
<i>Nauzelin</i>	6.1	2.4	4.0	5.7	5.5	2.5	4.2
<b>Other metabolic medicines</b>							
<i>NESP/ESPO</i>	--	21.3	34.4	43.0	43.7	22.4	35.1
<i>REGPARA</i>	--	1.9	3.3	4.2	4.6	2.9	4.6
<b>Blood and humoral applications</b>							
<i>Gran/Neu-up</i>	4.4	9.1	14.3	18.3	17.6	8.7	13.4
<b>Anticancer agents</b>							
<i>Farmorubicin + Adriacin</i>	8.7	3.8	5.9	7.7	7.4	3.4	5.1
<i>5-FU</i>	3.4	1.8	2.8	3.6	3.6	1.8	2.8
<i>Navelbine</i>	3.1	1.5	2.4	3.1	3.1	1.5	2.3
<b>Antiallergic agents</b>							
<i>Allelock</i>	23.3	9.6	15.6	23.1	25.0	10.6	16.4
<i>Celtect</i>	4.1	1.7	2.6	3.6	3.6	1.4	2.2
<b>Others</b>							
<i>Durotep</i>	13.9	--	--	--			
<b>Exports and Technology Out-Licensing</b>	16.3	22.8	26.3	29.7	29.1	10.8	14.7

Note 1: Figures for Fiscal year ended March 31, 2008 are unit sales of Kyowa Hakko Kogyo and do not include unit sales for Kirin Pharma.

Figures for period from April 1, 2008 to September 30, 2008 are the combined unit sales of Kirin Pharma and Kyowa Hakko Kogyo.

Note 2: Results based on settlement price on a shipment basis. Forecasts are based on an actual consumption basis.

Note 3: Fiscal year ended March 31, 2008 figures for Gran and Neu-up do not include unit sales of Gran produced by Kirin Pharma

**Kyowa Hakko Kogyo Co., Ltd.**
*Billions of yen, rounded down*

<b>Bio-Chemicals division (Non-Consolidated)</b>	April 1, 2007 to March 31, 2008	April 1, 2008 to March 31, 2009				April 1, 2009 to December 31, 2009	
	Full year results	April 1 to September 30 results	April 1 to December 31 results	Full year forecast (January 30)	Full year results	April 1 to September 30 forecasts	April 1 to December 31 forecasts
<b>Bio-chemical division total</b>	55.1	28.4	42.1	55.3	55.2	26.5	40.3
<b>Pharmaceuticals / Industrial raw materials</b>							
<b>Amino acids</b>	20.1	10.2	14.9	19.1	19.3	9.4	14.1
<b>Nucleic acids and vitamins</b>	5.1	2.9	4.0	5.1	5.0	2.0	3.0
<b>Health care products</b>	7.6	4.2	6.2	8.1	8.1	4.3	6.3
<b>Agrochemicals, livestock and fisheries products</b>	3.8	1.6	2.5	3.7	3.6	1.6	2.4
<b>Alcohol</b>	9.4	4.6	7.2	9.4	9.3	4.2	6.8

Note 1: Unit sales for Kyowa Hakko Bio-Chemical are included figures for FY 2008 Full year forecast following the separation in October 2008

*Billions of yen, rounded down*

<b>Chemicals division (Non-Consolidated)</b> (Kyowa Hakko Chemical Co., Ltd.)	April 1, 2007 to March 31, 2008	April 1, 2008 to March 31, 2009				April 1, 2009 to December 31, 2009	
	Full year results	April 1 to September 30 results	April 1 to December 31 results	Full year forecast (January 30)	Full year results	April 1 to September 30 forecasts	April 1 to December 31 forecasts
<b>Chemical division total</b>	107.9	57.1	77.3	90.0	89.2	31.0	50.0
<b>Solvents</b>	50.3	25.5	35.0	40.5	39.7	13.0	20.5
<b>Raw materials for plasticizers</b>	33.4	19.7	25.9	30.0	29.4	11.5	18.0
<b>Specialty chemicals</b>	19.3	9.7	13.2	16.3	16.4	6.5	11.0

*Billions of yen, rounded down*

<b>Food division (Non-Consolidated)</b> (Kyowa Hakko Food Specialties Co., Ltd.)	April 1, 2007 to March 31, 2008	April 1, 2008 to March 31, 2009				April 1, 2009 to December 31, 2009	
	Full year results	April 1 to September 30 results	April 1 to December 31 results	Full year forecast (January 30)	Full year results	April 1 to September 30 forecasts	April 1 to December 31 forecasts
<b>Food division total</b>	38.4	18.8	29.8	38.5	38.5		
<b>Natural seasonings</b>	15.3	7.3	11.7	15.8	15.0		
<b>Umami seasonings</b>	4.4	2.4	3.8	4.3	5.0		
<b>Bakery ingredients and products</b>	8.8	4.2	6.5	8.7	8.6		
<b>Processed foods</b>	7.0	3.1	5.0	6.7	6.6		



## R&D PIPELINE

### Kyowa Hakko Kirin (Phase II and onwards)

April 28, 2009

Category	Code Name Product Name	Stage		Indication	Formulation	In-house OR Licensed	Remarks
		Japan	Other countries				
Cancer/Hematology	KRN321 NESP	Filed Nov/2008		Anemia (After chemotherapy for cancer)	Injection	Kirin-Amgen	Long-acting erythropoiesis stimulating protein On sale in Japan for anemia of CKD patients on dialysis. since July 2007.
	AMG531	Phase III		Ideopathic thrombocytopenic purpura	Injection	Kirin-Amgen	Thrombopoiesis stimulating peptibody. (Contractual based development with Amgen Development Inc.)
	KW-2246	Phase III		Cancer pain	Sublingual tablet	Licensed from Orexo.	
	KRN125	Phase II		Neutropenia	Injection	Kirin-Amgen	Long-acting G-CSF
	AGS-003		Phase II in USA and Canada	Renal Cell Carcinoma	Injection	Developed with Argos.	Dendritic cell-based immunotherapeutics
	AGS-004		Phase II in Canada	HIV	Injection	Developed with Argos.	Dendritic cell-based immunotherapeutics
Kidney	PB94 PHOSBLOCK (RENEGAL)		Filed in China Jun/2008	Hyperphosphatemia	Oral	Licensed from Chugai.	Launched in Japan
	KRN 321 NESP	Filed Dec/2008	Phase II in China	☆ Anemia (Pre-dialysis)  ☆ Anemia (During dialysis)	Injection	Kirin-Amgen	Long-acting erythropoiesis stimulating protein On sale in Japan for anemia of CKD patients on dialysis. since July 2007.
Immunology/Allergy	KW-4679 ALLELOCK		Filed in China Jul/2008	Antiallergic	Oral	Developed In-house	Launched in Japan
	Z-206 ASACOL	Phase III		Inflammatory bowel disease (Crohn's disease)	Oral (pH depend controlled-release formulation)	Licensed from Zeria Pharma.	Jointly developed with Zeria Pharma.
CNS	KW-6002	Phase II b	Filed in USA Apr/2007	Parkinson's disease	Oral	☆ Developed In-house	☆ Clinical trials for monotherapy: Phase II a, in Japan
	KW-6500	Phase II		Parkinson's disease	Injection	Licensed from Britannia Pharma.	
Cardiovascular	KW-3049 CONIEL		Approved in China Sep/2008	☆ Angina	Oral	☆ Developed In-house	☆ Launched for Hypertension in China in Dec 2004 (Launched in Japan)
Other	KW-7158	Phase II a		Bowel disease (Irritable bowel syndrome)	Oral	Developed In-house	Development program for KW-7158 (Phase II a clinical trials) Overactive bladder/Urinary incontinence was discontinued in Sep 2006.

### Kyowa Hakko Kirin (Phase I)

Category	Code Name Product Name	Stage		Indication	Formulation	In-house OR Licensed	Remarks
		Japan	Other countries				
Cancer/Hematology	KRN654	Phase I / II		Essential thrombocythemia	Oral	Licensed from Shire.	
	KW-0761	Phase I		Cancer (Hematologic tumor)	Injection	Developed In-house	Humanized monoclonal antibody (The exclusive right to develop and commercialize for treatments other than cancer, and except in Japan, Korea, China and Taiwan, was transferred to Amgen in March 2008)
	KW-2449		Phase I / II a in USA	Cancer	Oral	Developed In-house	
	KW-2478		Phase I in Europe	Cancer	Injection	Developed In-house	
	ARQ 197	Phase I		Cancer	Oral	Licensed from ArQule.	
	KRN 330		Phase I in USA	Cancer	Injection	Developed In-house	Fully human monoclonal antibody
	BIW-8962		Phase I in USA	Cancer	Injection	Developed In-house	Human monoclonal antibody
Immunology/Allergy	NU206		Phase I in Australia	Inflammatory bowel disease	Injection	Developed with Nuvelo.	
	ASKP1240		Phase I in USA	Organ Transplant Rejection	Injection	Developed with Astellas.	Fully human monoclonal antibody Jointly developed with Astellas Pharma
Other	KW-3357	Phase I		Blood coagulation factor inhibitor (Disseminated intravascular coagulation)	Injection	Developed In-house	Recombinant antithrombin product
	KRN23		Phase I in USA	Hypophosphatemic disease such as X-linked Hypophosphatemia (XLH)	Injection	Developed In-house	Fully human monoclonal antibody

Additional pipeline products:

In the Philippines, approval for Filgrastim(G-CSF) has been filed

In Korea, Taiwan and Thailand, approval for NESP(long-acting erythropoiesis stimulating protein) has been filed

In Hong Kong and Taiwan, REGPARA (a treatment)

Updated since January 30th, 2009 (Area, Stage, Filed, Approved, Launched etc.)

☆ New indication